Gapping up
In reaction to strong earnings/guidance: SURG +4.7%, MTG +2.3%, CSX +1.8%, HPQ +1.8%, NHTC +1.5%, BLK +1.4%, BAC +0.7%, PNC +0.5%, .
M&A news: CSRE +30.5% (Qualcomm (QCOM) to acquire CSR for ~$2.5 bln)
Select Ebola related names showing strength: APT +24.3%, LAKE +16.2%, IBIO +10%, HEB +6.3%, NLNK +6.1%, CERS +3.7%, CMRX +3.3%, SRPT +3.1%, TKMR +3%, INO +2.1%, NNVC +1.4%
Other news: ANN +8.2% (Golden Gate Capital files amended 13D with Confidentiality Agreement dated today Oct 14), NAVB +7.3% (FDA approves expanded use of Navidea's Lymphoseek for lymphatic mapping in solid tumors), GTAT +4.9% (Apple (AAPL) wants to secretly challenge GTAT bankruptcy, according to reports), MPO +4.3% (provides hedging update; 1212K barrels/day through 2Q15 at avg. ~$90/bbl), STRP +1.2% (after 18% move higher on earnings yesterday), SSRI +1.1% (analyst tour at Marigold highlights life of mine plan and exploration results), AMD +1.1% (in symp with INTC earnings), CCL +0.9% (Carnival and largest Chinese Shipyard sign Memo of Understanding aimed at growing the cruise industry in China), .
Analyst comments: PTEN +2% (initiated with a Buy at Citigroup), UNFI +1.9% (upgraded to Overweight from Neutral at Piper Jaffray), EXXI +1.5% (upgraded to Buy from Neutral at Global Hunter Securities), SWIR +1.1% (initiated with a Outperform at Northland Capital), CBS +1.1% (upgraded to Buy from Neutral at Citigroup), AMAT +0.8% (upgraded to Buy from Neutral at BofA/Merrill), RAX+0.6% (upgraded to Outperform from Sell at Credit Agricole), HST +0.5% (upgraded to Overweight from Equal Weight at Barclays)
In reaction to strong earnings/guidance: SURG +4.7%, MTG +2.3%, CSX +1.8%, HPQ +1.8%, NHTC +1.5%, BLK +1.4%, BAC +0.7%, PNC +0.5%, .
M&A news: CSRE +30.5% (Qualcomm (QCOM) to acquire CSR for ~$2.5 bln)
Select Ebola related names showing strength: APT +24.3%, LAKE +16.2%, IBIO +10%, HEB +6.3%, NLNK +6.1%, CERS +3.7%, CMRX +3.3%, SRPT +3.1%, TKMR +3%, INO +2.1%, NNVC +1.4%
Other news: ANN +8.2% (Golden Gate Capital files amended 13D with Confidentiality Agreement dated today Oct 14), NAVB +7.3% (FDA approves expanded use of Navidea's Lymphoseek for lymphatic mapping in solid tumors), GTAT +4.9% (Apple (AAPL) wants to secretly challenge GTAT bankruptcy, according to reports), MPO +4.3% (provides hedging update; 1212K barrels/day through 2Q15 at avg. ~$90/bbl), STRP +1.2% (after 18% move higher on earnings yesterday), SSRI +1.1% (analyst tour at Marigold highlights life of mine plan and exploration results), AMD +1.1% (in symp with INTC earnings), CCL +0.9% (Carnival and largest Chinese Shipyard sign Memo of Understanding aimed at growing the cruise industry in China), .
Analyst comments: PTEN +2% (initiated with a Buy at Citigroup), UNFI +1.9% (upgraded to Overweight from Neutral at Piper Jaffray), EXXI +1.5% (upgraded to Buy from Neutral at Global Hunter Securities), SWIR +1.1% (initiated with a Outperform at Northland Capital), CBS +1.1% (upgraded to Buy from Neutral at Citigroup), AMAT +0.8% (upgraded to Buy from Neutral at BofA/Merrill), RAX+0.6% (upgraded to Outperform from Sell at Credit Agricole), HST +0.5% (upgraded to Overweight from Equal Weight at Barclays)